-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics
NEW YORK, NY / ACCESSWIRE / December 20, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Eterna Therapeutics.
Toni had the pleasure of recently conducting the Interview with Dr. Matt Angel, CEO of Eterna Therapeutics (NASDAQ:ERNA). Toni diligently focused on questions she thought would be on the minds of most current and potential future shareholders. See interview highlights below.
Access this interview in its entirety at
Matt Angel, PhD
Chief Executive Officer
Dr. Matt Angel, PhD, is currently the interim CEO, bringing a wealth of biotechnology executive experience to Eterna. He led Factor Bioscience Inc. as CEO since its founding in 2011 and was co-founder of Novellus Therapeutics and Exacis Biotherapeutics. Dr. Angel possesses deep experience in cell therapy product development, intellectual property protection and licensing, and contract negotiations, including collaboration and licensing agreements. He has raised more than $150 million through grants, equity financings, and mergers and acquisitions. A pioneer in mRNA technology, Dr. Angel is a prolific inventor with more than 100 patents covering mRNA, nucleic acid delivery, gene editing, and cell reprogramming technologies. Dr. Angel received his PhD from the Massachusetts Institute of Technology, where he studied immunology and synthetic RNA.
Interview Highlights:
Traders News Source Editor Toni Loudenbeck and Dr. Matt Angel cover an overview of the company, attributes of ERNA's cell engineering technology, current and near-term research studies in process both internally and through partnerships, the ERNA IP portfolio, potential near-term catalyst at ERNA that could be the biggest benefit to shareholders plus much more in this interview.
Access this interview in its entirety at
About Eterna Therapeutics
Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology. Its mission is to realize the potential of cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key cell engineering technologies, including what it believes are the most widely used methods for therapeutic gene editing currently in clinical development. Eterna has multiple next-generation cell and gene-editing therapies in preclinical development for various indications. The Company plans to advance its technology and pipeline both internally and through strategic partnerships. For more information, please visit .
Investor Relations Contact:
investors@eternatx.com
About Traders News Source (TNS)
Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit:
Media Contact
Traders News Source
Mark Roberts, Senior Editor/Interviewer
Editor@TradersNewsSource.com
SOURCE: Traders News Source LLC
View source version on accesswire.com:
NEW YORK, NY / ACCESSWIRE / December 20, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Eterna Therapeutics.
纽约州纽约/ACCESSWIRE/2022 年 12 月 20 日/ 专注于中小型上市公司的领先独立股票研究和企业准入公司Traders News Source最近对Eterna Therapeutics进行了新的C级采访。
Toni had the pleasure of recently conducting the Interview with Dr. Matt Angel, CEO of Eterna Therapeutics (NASDAQ:ERNA). Toni diligently focused on questions she thought would be on the minds of most current and potential future shareholders. See interview highlights below.
托尼最近有幸对Eterna Therapeutics(纳斯达克股票代码:ERNA)首席执行官马特·安吉尔博士进行了采访。托尼努力地专注于她认为大多数当前和潜在的未来股东会想到的问题。请参阅下面的采访要点。
Access this interview in its entirety at
访问此访谈的完整内容
Matt Angel, PhD
马特·安吉尔,博士
Chief Executive Officer
首席执行官
Dr. Matt Angel, PhD, is currently the interim CEO, bringing a wealth of biotechnology executive experience to Eterna. He led Factor Bioscience Inc. as CEO since its founding in 2011 and was co-founder of Novellus Therapeutics and Exacis Biotherapeutics. Dr. Angel possesses deep experience in cell therapy product development, intellectual property protection and licensing, and contract negotiations, including collaboration and licensing agreements. He has raised more than $150 million through grants, equity financings, and mergers and acquisitions. A pioneer in mRNA technology, Dr. Angel is a prolific inventor with more than 100 patents covering mRNA, nucleic acid delivery, gene editing, and cell reprogramming technologies. Dr. Angel received his PhD from the Massachusetts Institute of Technology, where he studied immunology and synthetic RNA.
马特·安吉尔博士目前是临时首席执行官,为Eterna带来了丰富的生物技术高管经验。自2011年成立以来,他领导Factor Bioscience Inc.担任首席执行官,也是Novellus Therapeutics和Exacis BiotherapAngel 博士在细胞疗法产品开发、知识产权保护和许可以及合同谈判(包括合作和许可协议)方面拥有丰富的经验。他通过补助金、股权融资和兼并收购筹集了超过1.5亿美元。作为 mRNA 技术的先驱,Angel 博士是一位多产的发明家,拥有 100 多项专利,涉及 mRNA、核酸递送、基因编辑和细胞重编程技术。Angel 博士在麻省理工学院获得博士学位,在那里他研究了免疫学和合成 RNA。
Interview Highlights:
访谈要点:
Traders News Source Editor Toni Loudenbeck and Dr. Matt Angel cover an overview of the company, attributes of ERNA's cell engineering technology, current and near-term research studies in process both internally and through partnerships, the ERNA IP portfolio, potential near-term catalyst at ERNA that could be the biggest benefit to shareholders plus much more in this interview.
Traders News Source编辑托尼·劳登贝克和马特·安吉尔博士报道了公司概述、ERNA细胞工程技术的属性、内部和通过合作伙伴关系进行的当前和短期研究、ERNA的IP投资组合、ERNA的潜在短期催化剂,这可能为股东带来最大收益,以及本次采访中的更多内容。
Access this interview in its entirety at
访问此访谈的完整内容
About Eterna Therapeutics
关于埃特纳疗法
Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology. Its mission is to realize the potential of cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key cell engineering technologies, including what it believes are the most widely used methods for therapeutic gene editing currently in clinical development. Eterna has multiple next-generation cell and gene-editing therapies in preclinical development for various indications. The Company plans to advance its technology and pipeline both internally and through strategic partnerships. For more information, please visit .
Eterna 专注于使用最先进的 mRNA 细胞工程技术开发先进的疗法。其使命是实现细胞工程的潜力,为患者提供变革性新药。该公司已授权了100多项专利,涵盖关键的细胞工程技术,包括它认为目前临床开发中最广泛使用的治疗性基因编辑方法。Eterna 有多种下一代细胞和基因编辑疗法正在临床前开发中,适用于各种适应症。该公司计划在内部和通过战略合作伙伴关系推进其技术和产品线。欲了解更多信息,请访问。
Investor Relations Contact:
investors@eternatx.com
投资者关系联系人:
investors@eternatx.com
About Traders News Source (TNS)
关于交易者新闻来源(TNS)
Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit:
Traders News Source是一家领先的独立股票研究和企业准入公司,专注于在重大举措之前发现和报告下一个热门股票和市场板块。TNS还是一家金融新闻提供商,致力于让投资者直接接触有前途的上市公司的首席执行官和市场专家。我们的高管级访谈回答了大多数当前和未来股东心目中的一些棘手问题。TNS C级访谈为一些最有前途的中小型上市公司的运营和管理方向提供了宝贵的见解。要查看 TNS 披露声明,请访问:
Media Contact
媒体联系人
Traders News Source
交易者新闻来源
Mark Roberts, Senior Editor/Interviewer
Editor@TradersNewsSource.com
马克·罗伯茨,高级编辑/面试官
Editor@TradersNewsSource.com
SOURCE: Traders News Source LLC
来源: 交易者新闻来源有限责任公司
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧